Navigation Links
New drug shows potential for treatment-resistant leukemia
Date:4/11/2011

BOSTON (April 11) --A study from Tufts Medical Center researchers published today finds that a novel drug shows promise for treating leukemia patients who have few other options because their disease has developed resistance to standard treatment.

Appearing in the journal Cancer Cell, the study is the first published report showing that the drug, DCC-2036, fights chronic myeloid leukemia (CML) in a mouse model of the disease and is effective against human leukemia cells.

"These findings demonstrate that DCC-2036 is an excellent candidate for clinical development as a treatment for resistant CML. Not all drugs that work in a test tube will actually be effective in a living organism such as our mouse model," said Richard Van Etten, MD, PhD, Director of Tuft's Medical Center's Cancer Center and senior author of the study.

Other authors of the study are scientists with Deciphera Pharmaceuticals LLC of Lawrence, Kansas, and Emerald Biostructures of Bainbridge Island, WA.

DCC-2036 is a tyrosine kinase inhibitor (TKI), a class of drugs that block the action of an abnormal enzyme, BCR-ABL1, that sends chemical messenges that tell CML cells to grow. The development of TKI drugs such as imatinib (Gleevec) dramatically improved the prognosis for patients with CML, which strikes about 5,000 new patients each year in the United States. But about a third of patients will eventually relapse, principally because of mutations that render BCR-ABL1 resistant to the TKI. Such patients are left with few treatment options other than bone marrow transplantation.

The study showed that in human cells taken from treatment-resistant patients who had received the new drug, DCC-2036 tamped down the mutant enzyme that led to their relapse. The study also found that the drug killed malignant cells and prolonged survival in a mouse model of CML developed by Van Etten's team.

Deciphera Pharmaceuticals, LLC used crystal structures of BCR-ABL1 to custom-design the novel drug to inhibit the mutant enzyme that leads to treatment resistance in CML patients. "The study illustrates the power of designing drugs based upon structures of the target and initial testing of these drugs in mouse models before proceeding to the clinic. This type of targeted design is a paradigm for how cancer treatments will be developed in the 21st century," Van Etten said.


'/>"/>

Contact: Julie Jette
jjette@tuftsmedicalcenter.org
617-636-3265
Tufts Medical Center
Source:Eurekalert

Related medicine news :

1. Brain Tumor Vaccine Shows Promise in Early Trials
2. Warning labels better than a fat tax, University of Alberta study shows
3. Unemployment Plays Role in Early Deaths, Research Shows
4. Research shows blood protein levels may predict risk of a cardiovascular event: Study
5. Long-term study shows that kidney transplants are faring better than previously reported
6. New drug shrinks cancer in animals, U-M study shows
7. Simple chemical cocktail shows first promise for limb re-growth in mammals
8. Elevated levels of sodium blunt response to stress, study shows
9. Study shows that modern surgery for scoliosis has good long-term outcomes
10. Minimally Invasive Heart-Valve Procedure Shows Promise: Study
11. PegIFN-lambda shows superior virological response and improved safety than PegIFN-alpha-2a
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... ... ... 'Tis the season for family, festivity, food and fun! Temptation abounds, and parties ... healthy, staying active, and taking medication and doing daily foot health checks (a must ... trips, parties and family gatherings can take their toll on our feet during the ...
(Date:12/6/2016)... ... December 06, 2016 , ... ... authorized OSHA Training Institute Education Center headquartered in Northern California, has announced the ... providing occupational safety and health training to public sector employees. , “The primary ...
(Date:12/5/2016)... ... 2016 , ... Edward Buckingham MD , and the ... the newest Sciton laser in January 2017. The Halo is the first and ... wavelengths for exceptional results. Outperforming more traditional lasers, the innovative Halo automatically customizes ...
(Date:12/5/2016)... Petersburg, Fla. (PRWEB) , ... December 05, 2016 , ... ... concussions have on the growing brains of young athletes. Over the course of three ... the head through unique mouth guards. The mouth guards, equipped with special sensors, will ...
(Date:12/5/2016)... ... December 05, 2016 , ... ... company will provide alerting technology to Central Illinois Health Information Exchange (CIHIE) ... in federal funds as the sole sub-recipient participating with the Illinois Health ...
Breaking Medicine News(10 mins):
(Date:12/6/2016)... , Dec. 6, 2016 In this age ... to be hopeful.  A special kind of sunglasses, from ... anxious life. Photo - http://photos.prnewswire.com/prnh/20161205/445444 ... Robert Buck, the psychotherapist who developed and patented the ... to overcoming anxiety and worry.  "Anxiety doesn,t have ...
(Date:12/5/2016)... , Dec. 5 2016 United ... Summary GlobalData,s new report, "United Kingdom ... key market data on the United Kingdom Ophthalmic ... millions of US dollars, volume (in units) and ... Coherence Tomography (OCT), Retinal Ultrasound Imaging Systems, Corneal ...
(Date:12/5/2016)...   Mallinckrodt Pharmaceuticals (NYSE: MNK ... that it received a perfect score of 100 percent ... benchmarking survey and report on corporate policies and practices ... equality, administered by the Human Rights Campaign (HRC) Foundation. ... which also earned top marks this year. ...
Breaking Medicine Technology: